Navigation Links
Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema

vailable in the second half of 2007 after the data have been collected, verified and analyzed. In addition to the pivotal CHANGE trial, Lev has initiated two open-label studies to provide HAE patients with continued access to C1-INH.

Lev intends to submit a Biologics License Application, or BLA, to the U.S. Food and Drug Administration, or FDA, during the second quarter of 2007 for marketing approval of C1-INH for the acute treatment of HAE attacks based on the results of the first portion of the CHANGE study. The results from the prophylactic portion of the study, when available and if supportive, are expected to be used to expand the label indication.

About Hereditary Angioedema

HAE is a genetic disorder characterized by recurrent attacks of inflammation affecting the extremities (the hands and feet), the face, the abdomen, and the larynx. The inflammation can be disfiguring, debilitating, or, in the case of laryngeal attacks, life-threatening. HAE is caused by a deficiency of the plasma protein C1-INH. While there is no approved therapy for the condition in the U.S., replacement therapy with C1-INH is the treatment of choice for HAE in Europe, where it has been used safely and effectively for over 30 years. There are estimated to be approximately 10,000 people with HAE in the U.S.

About Lev Pharmaceuticals, Inc.

Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. The Company is also evaluating the development of C1-INH for the treatment of acute myocardial infarction, or heart attack, and selective other diseases and disorders in which inflammation is known or believed to play an underlying role. Lev's C1-INH has been granted orphan drug status for the treatment and prevention of HAE, potentially securing, upon approval, market exclusivity for seven years. The Company has also received fast track designation status from the FDA, which facil
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:5/29/2015)... May 29, 2015 /CNW/ - Alliance Principle Ingredients/Neutrical Solutions ... the health product Galenic Health Ginger in Bentonite ... for adolescents and children. The product currently contains ... but within acceptable limits for adult dosing. ... digestive upset and disturbances. Alliance Principle Ingredients / ...
(Date:5/29/2015)... , May 28, 2015 Research and ... the "North America MRI Market - Growth, Trends ... offering. The North American MRI systems market ... in 2014 to $1.58 billion by 2020 with a ... are of three types namely, the open system, closed ...
(Date:5/29/2015)...  Dr. Yair Walzer has added a leading ... often caused by menopause. The MonaLisa Touch™, an in-office procedure ... clearance in 2014. Dr. Walzer is one of the first ... special fractional CO 2 laser specifically designed to help ... In 2010 there were greater than 46M women between ...
Breaking Medicine Technology:North America MRI Market - Growth, Trends And Forecasts 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare & Toshiba Medical Systems Dominating 2The Newest FDA-Cleared Breakthrough In Women's Health Treatments 2
... achieved with proprietary drug combination ... ... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ), today announced positive results from,a ... and chronic obstructive pulmonary disease (COPD). MAP0005 is a,single-particle combination of ...
... QMed, Inc.,(Nasdaq: QMED ) today announced it ... the Centers for Medicare and Medicaid Services (CMS) ... Northern,California., In 2002, The CMS selected 15 ... coordinated care services to Medicare fee-for-service,beneficiaries with complex ...
Cached Medicine Technology:MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 2MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 3MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics 4QMed, Inc. Receives 2-Year Extension of Medicare Coordinated Care Demonstration Project by CMS 2
(Date:5/30/2015)... 2015 Promising clinical trial results presented ... Meeting 2015 show activity of the investigational anti-cancer agent ... against brain metastases and in another case in overall ... "I am thrilled to have been able to offer ... She didn't have any other great treatment options that ...
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 NovaSure® endometrial ... lighten or stop periods, without the side effects ... can reduce or stop menstrual bleeding and works by ... (the part that causes the bleeding), with a quick ... suffer from heavy menstrual bleeding. Many women begin ...
(Date:5/30/2015)... (PRWEB) May 30, 2015 The results ... crocidolite asbestos has a high potential to cause mesothelioma, ... full story now on the Surviving Mesothelioma website. ... of Occupational Medicine in Lodz, Poland found that, among ... workers between 1970 and 2012, all of them happened ...
(Date:5/30/2015)... 30, 2015 One of the pervasive ... local healthcare options available. Often, the ruralness of a ... those in rural areas feeling the crunch of a ... or tired of paying high premiums and copays, ... with licensed physicians via the power of the internet. ...
Breaking Medicine News(10 mins):Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:Women's Excellence Now Provides NovaSure Treatment 2Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 2Health News:Online USA Doctors Brings Healthcare to the Masses with New E-Consults 3
... on Health releases nationwide eValue8,findings, SCOTTSDALE, ... eValue8,(TM) report of health plan performance released ... Health (NBCH), health plans could do a,better ... customers, enabling,improvements in patient safety, care coordination, ...
... The American Cancer Society,is looking for individuals with ... interest in the battle against cancer to serve on ... funded by the,organization,s research and training grants. These "stakeholders" ... as having had a,family member with cancer, having been ...
... kill them, study finds , , MONDAY, Nov. 12 (HealthDay ... weapons that helps make community-associated methicillin-resistant Staphylococcus aureus ... be done, the study "provides a partial explanation of ... and gives a starting point in the development of ...
... WASHINGTON, Nov. 12 Psoriasis Cure Now has,selected its ... contest.,Brendan Hayward of Santa Monica, California walks away with ... to the wire. Eight other,Finalists each will receive $250 ... be viewed at, http://www.psoriasis-cure-now.org/contest/videos.php ., "Brendan Hayward ...
... Health,Systems, Inc. (Amex: ADK ) announced today ... on Wednesday, November 14th, 2007. In conjunction,with the ... on November,15th, at 4:15 EST. The telephone number ... to participate at that time, playback is,available through ...
... HLM Venture Partners announced today,that it has led ... Inc. CaseNET, based in Waltham, MA, is an early-stage ... government,agencies a software solution for medical and care management. ... to the round and was joined,by existing investors Sigma ...
Cached Medicine News:Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4Health News:American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 2Health News:Key to MRSA Virulence in Community Discovered 2Health News:Key to MRSA Virulence in Community Discovered 3Health News:Psoriasis Cure Now Video Contest $7,500 Grand Prize Winner Announced 2Health News:AdCare Health Systems, Inc. Announces 2007 Third Quarter Earnings Release and Conference Call Schedule 2Health News:HLM Venture Partners Leads Series B Financing of CaseNET, Inc. 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Standard type 1/1 (mm), opening width 8.0 mm and length 8 mm....
... The BacT/Alert 3D Signature is ... microbial detection system that integrates blood, ... It is a powerful microbiology workstation ... for higher volume identification and where ...
... The Vitek is a completely automated instrument ... of 2 - 6 hour same day ... quality control module. It is used for ... and urine screening and has a complete ...
IDS Rapid One, a microbial identification system....
Medicine Products: